Table 4.
Influence of the severity of COVID-19 on the development of long-COVID symptoms in the whole study group and within the individual cohorts of immunocompromised and immunocompetent children
| Severity of COVID-19 and the prevalence of long-COVID < 12-week post-infection | |||||
|---|---|---|---|---|---|
| Asymptomatic | Mild | Moderate | Severe | p | |
| Whole study group | 8 (19.1%) | 30 (46.9%) | 22 (68.8%) | 7 (77.8%) | < 0.01 |
| ID ( +) | 5 (15.6%) | 12 (44.4%) | 5 (62.5%) | 2 (66.7%) | 0.01 |
| ID (-) | 3 (30.0%) | 18 (48.7%) | 17 (70.9%) | 5 (83.3%) | 0.02 |
| Severity of COVID-19 and the prevalence of long-COVID > 12-week post-infection | |||||
|---|---|---|---|---|---|
| Asymptomatic | Mild | Moderate | Severe | p | |
| Whole study group | 3 (7.1%) | 10 (15.6%) | 13 (40.6%) | 6 (66.7%) | < 0.01 |
| ID ( +) | 2 (6.25%) | 2 (7.4%) | 3 (37.5%) | 2 (66.7%) | 0.02 |
| ID (-) | 1 (10.0%) | 8 (21.6%) | 10 (41.7%) | 4 (66.7% | 0.01 |
ID ( +), children with immunodeficiency; ID (-), children without immunodeficiency